Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling

Johanna C. Bendell, Susanna V. Ulahannan, M. Koczywas, Julie R. Brahmer, Anna Capasso, S. Gail Eckhardt, Michael S. Gordon, Caroline E. McCoach, Misako Nagasaka, Kimmie Ng, Jorge H. Limón-Pacheco, Jonathan W. Riess, Alexander I. Spira, Conor Steuer, Richa Dua, Suramanyam Chittivelu, Serena Masciari, Z. Wang, X. Wang, S.‐H.I. Ou